SMD100_SAINTMED

Dr. Wirot Wasusuttikulkan, Chief Executive Officer of SMD Rise Public Company Limited, or SMD100, informed the Stock Exchange that the company's board meeting on October 2, 2026 approved the establishment of a new subsidiary to provide medical diagnostic imaging technology services in Thailand, covering X-ray, Ultrasound, CT Scan, PET/CT, MRI, radiation therapy, and digital health solutions, serving hospitals and related project customers. The new subsidiary is named SMD Remag (Thailand) Company Limited, with registered capital of 10 million baht, in which SMD100 holds 51% and Remag Group (Thailand) Company Limited holds 49%. The company expects to begin recognizing revenue from this business in the second quarter of 2027, using the company's working capital as the funding source for the establishment. At the same time, the meeting also approved the dissolution of SMD Pharmatics Company Limited, a wholly owned subsidiary that imports and distributes automated medication dispensing systems and related equipment and provides full installation and system integration services, due to financial performance that did not meet targets. The dissolution does not significantly affect the company's operations or financial position.

SMD Rise Public Company Limited, or SMD100, reported second-quarter 2569 results, swinging to a net profit of 28.65 million baht, up 308.21 percent from a loss of 13.76 million baht in the same quarter last year. Total revenue was 321.23 million baht, up 99.66 percent, supported by medical device and equipment sales growth of 103.06 percent, especially in sleep medicine, critical care, and radiology. Service revenue rose 72.33 percent from sleep testing services. As a result, the first half of 2569 saw its net loss narrow to 1.89 million baht from a loss of 40.23 million baht in the first half of 2568, with total revenue of 493.95 million baht, up 57.81 percent year on year. The company's backlog stood at 272.36 million baht, with critical care accounting for 43.52 percent of total backlog, followed by sleep medicine at 23.73 percent and health services at 20.10 percent.

SMD Rise, or SMD100, has joined the Stock Exchange of Thailand's JUMP+ program to enhance business potential and governance, setting a revenue growth target of 20 to 30 percent for 2026 from the previous year's revenue of approximately 922 million baht, and aiming to push net profit to 80 to 120 million baht by 2028. The company plans to increase the revenue share from sleep medicine and medical technology businesses, building a comprehensive healthcare ecosystem covering diagnosis through to services and solutions for hospitals and healthcare facilities. In addition, the company emphasizes governance enhancement through anti-corruption measures, a whistleblower system, and prevention of insider information use, which are part of the JUMP+ program that helps increase transparency and investor confidence.